ResMed (RMD) Competitors

$216.98
-1.17 (-0.54%)
(As of 05/3/2024 ET)

RMD vs. BAX, DXCM, PODD, TFX, BDX, BSX, WST, SWAV, SOLV, and BIIB

Should you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Baxter International (BAX), DexCom (DXCM), Insulet (PODD), Teleflex (TFX), Becton, Dickinson and Company (BDX), Boston Scientific (BSX), West Pharmaceutical Services (WST), Shockwave Medical (SWAV), Solventum (SOLV), and Biogen (BIIB). These companies are all part of the "medical" sector.

ResMed vs.

ResMed (NYSE:RMD) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.

Baxter International received 313 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 66.30% of users gave Baxter International an outperform vote while only 52.93% of users gave ResMed an outperform vote.

CompanyUnderperformOutperform
ResMedOutperform Votes
415
52.93%
Underperform Votes
369
47.07%
Baxter InternationalOutperform Votes
728
66.30%
Underperform Votes
370
33.70%

ResMed has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

55.0% of ResMed shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 1.2% of ResMed shares are owned by insiders. Comparatively, 0.2% of Baxter International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ResMed pays an annual dividend of $1.92 per share and has a dividend yield of 0.9%. Baxter International pays an annual dividend of $1.16 per share and has a dividend yield of 3.1%. ResMed pays out 29.5% of its earnings in the form of a dividend. Baxter International pays out 22.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Baxter International is clearly the better dividend stock, given its higher yield and lower payout ratio.

ResMed has a net margin of 20.91% compared to Baxter International's net margin of 17.77%. ResMed's return on equity of 24.43% beat Baxter International's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed20.91% 24.43% 15.70%
Baxter International 17.77%19.49%4.77%

Baxter International has higher revenue and earnings than ResMed. Baxter International is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$4.22B7.55$897.56M$6.5133.33
Baxter International$14.81B1.26$2.66B$5.227.07

ResMed currently has a consensus price target of $202.80, suggesting a potential downside of 6.54%. Baxter International has a consensus price target of $46.30, suggesting a potential upside of 25.51%. Given Baxter International's higher possible upside, analysts plainly believe Baxter International is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.70
Baxter International
0 Sell rating(s)
7 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.22

In the previous week, Baxter International had 12 more articles in the media than ResMed. MarketBeat recorded 34 mentions for Baxter International and 22 mentions for ResMed. ResMed's average media sentiment score of 0.68 beat Baxter International's score of 0.51 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
7 Very Positive mention(s)
5 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Baxter International
9 Very Positive mention(s)
2 Positive mention(s)
16 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ResMed beats Baxter International on 10 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RMD vs. The Competition

MetricResMedSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$31.88B$3.84B$4.95B$17.43B
Dividend Yield0.89%2.16%2.86%3.58%
P/E Ratio33.3319.65263.8425.58
Price / Sales7.5571.372,429.2812.18
Price / Cash27.5344.8448.4017.50
Price / Book6.884.374.864.92
Net Income$897.56M$4.51M$103.62M$964.63M
7 Day Performance-0.50%3.22%3.88%1.73%
1 Month Performance17.29%-3.69%-3.19%-1.32%
1 Year Performance-6.51%10.24%5.74%101.87%

ResMed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BAX
Baxter International
4.9609 of 5 stars
$40.37
-0.7%
$46.30
+14.7%
-20.7%$20.50B$14.81B7.7360,000Earnings Report
Options Volume
News Coverage
DXCM
DexCom
4.9593 of 5 stars
$127.39
+1.3%
$141.67
+11.2%
+9.4%$50.66B$3.62B82.199,600Analyst Upgrade
PODD
Insulet
4.8966 of 5 stars
$171.94
+1.0%
$243.21
+41.5%
-45.7%$12.04B$1.70B59.093,000Upcoming Earnings
Positive News
TFX
Teleflex
4.9236 of 5 stars
$208.75
+0.1%
$267.50
+28.1%
-25.4%$9.83B$2.97B27.7214,500Earnings Report
Analyst Report
News Coverage
BDX
Becton, Dickinson and Company
4.9293 of 5 stars
$234.60
+0.5%
$280.00
+19.4%
-11.0%$67.78B$19.37B55.5973,000Earnings Report
Dividend Announcement
Insider Selling
News Coverage
BSX
Boston Scientific
4.3576 of 5 stars
$71.86
-0.9%
$75.09
+4.5%
+38.3%$105.43B$14.24B60.3948,000Insider Selling
WST
West Pharmaceutical Services
4.8494 of 5 stars
$357.40
+0.8%
$435.20
+21.8%
-0.9%$26.03B$2.95B47.1510,600
SWAV
Shockwave Medical
4.6529 of 5 stars
$330.19
+0.2%
$309.11
-6.4%
+17.4%$12.35B$730.23M85.321,468Positive News
SOLV
Solventum
0 of 5 stars
$65.01
-1.4%
$69.50
+6.9%
N/A$11.21BN/A0.00N/AUpcoming Earnings
News Coverage
BIIB
Biogen
4.9902 of 5 stars
$214.82
-0.3%
$293.88
+36.8%
-30.1%$31.28B$9.84B26.827,570Analyst Report

Related Companies and Tools

This page (NYSE:RMD) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners